Parenteral Analgesics Market (2026 - 2033)

Parenteral Analgesics Market Summary

The global parenteral analgesics market size was valued at USD 5.0 billion in 2025 and is projected to grow from USD 5.2 billion in 2026 to USD 7.5 billion by 2033, at a CAGR of 5.4% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 41.2% in 2025. The market growth is driven by the rising demand for pain management in surgical procedures, post-operative recovery, and emergency departments.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The parenteral analgesics industry comprises injectable medicines used to manage pain when rapid relief is required or oral administration is unsuitable. These medicines are administered mainly through intravenous, intramuscular, and subcutaneous routes in hospitals and other clinical care settings. The market includes opioid analgesics, non-opioid analgesics, and other injectable medicines used for pain control. Product selection depends on the cause and severity of pain, the patient’s clinical condition, the required onset of action, and the duration of treatment. Parenteral analgesics are used in emergency care, surgery, post-operative recovery, and the management of pain associated with certain acute and chronic conditions. Hospitals remain an important point of use because injectable pain medicines require clinical assessment, dose selection, administration, and monitoring. Demand is also linked to surgical activity, emergency admissions, and access to healthcare services that provide supervised pain management, including recovery and critical care units.

To learn more about this report, Download Free Sample Report

Acute pain management is an important area of use, particularly after surgery, trauma, and during emergency treatment. Injectable medicines are also used when patients cannot take oral medicines or when a controlled dose is required under clinical supervision. Chronic pain treatment is more varied, and parenteral analgesics are generally used for selected clinical needs rather than as a routine option for every patient with persistent pain. The wider burden of pain supports the need for effective treatment, although not all people experiencing pain require injectable medicines. Treatment decisions depend on the underlying condition, patient response, safety considerations, and the availability of alternative pain management options. Multimodal pain management, which combines medicines with different mechanisms of action, also supports the use of selected injectable analgesics in surgical and hospital care.

Market demand is shaped by clinical guidelines, product availability, hospital purchasing practices, medicine prices, and national rules for controlled substances. Opioid analgesics remain relevant for severe pain, but their use requires attention to dosage, adverse effects, dependence risks, and prescribing controls. Non-opioid injectable medicines provide options for selected pain management needs and can be used as part of multimodal treatment, depending on the patient and procedure. Manufacturers compete through product range, supply reliability, regulatory compliance, and relationships with hospitals and distributors. Shortages of active ingredients or finished injectable products can affect access, while sterile manufacturing requirements and quality controls influence production and supply. The market also differs across regions because healthcare infrastructure, surgical services, reimbursement policies, and access to pain specialists vary. Demand will depend on clinical need, safe prescribing, product supply, and the availability of injectable analgesics within hospital care.

Market Dynamics

Market Characteristics & Concentration

Innovation in the parenteral analgesics market is moderate because much of the product portfolio consists of established medicines, including injectable opioids, acetaminophen, and nonsteroidal anti-inflammatory drugs. Product development focuses on formulation improvements, dosing convenience, drug stability, administration methods, and manufacturing efficiency. Ready-to-administer presentations and premixed formulations can reduce preparation requirements in hospitals and support consistent medicine administration. Research into non-opioid pain management also creates opportunities for products that address pain while reducing reliance on opioids in suitable patients. However, developing new injectable analgesics requires clinical evidence, regulatory review, and investment in sterile manufacturing. Generic manufacturers also focus on developing approved equivalents of existing products. Consequently, innovation is driven by both product development and improvements in formulation and manufacturing processes rather than by frequent changes in established analgesic drug classes.

To learn more about this report, Download Free Sample Report

Entry barriers in the parenteral analgesics industry are high because injectable medicines require specialized manufacturing processes, sterile production facilities, quality testing, and regulatory approval. Manufacturers must demonstrate product quality, safety, and consistency before supplying hospitals and other healthcare providers. Establishing sterile manufacturing capacity requires investment in equipment, environmental controls, trained personnel, and quality management systems. Products containing controlled substances also require compliance with additional manufacturing, storage, distribution, and recordkeeping requirements. New entrants must establish reliable access to active pharmaceutical ingredients, packaging materials, and distribution channels. Hospital procurement processes can further limit access for companies without an established supply record or approved products. Generic manufacturers also face competition from suppliers with existing production capacity and established customer relationships. These factors make entry difficult for companies without relevant manufacturing experience, regulatory capabilities, and sufficient financial resources.

Regulations have a high impact on the parenteral analgesics market because injectable medicines must meet requirements for product approval, sterile manufacturing, quality control, labeling, and distribution. Regulatory authorities assess the safety, quality, and efficacy of products before granting marketing authorization. Manufacturing facilities must comply with applicable good manufacturing practice requirements, while product testing helps maintain batch consistency and reduce contamination risks. Opioid analgesics face additional controls because of their potential for misuse, dependence, and overdose. These controls affect prescribing, storage, recordkeeping, and distribution. Regulatory requirements differ across countries, increasing the time and resources required to introduce products across multiple markets. Companies must also maintain compliance after approval through quality monitoring and reporting obligations. Changes in regulatory requirements can affect production costs, product availability, and market access for manufacturers supplying hospital injectable medicines.

The market faces moderate substitution pressure from oral analgesics, topical pain medicines, regional anesthesia, and other pain management methods. Oral medicines are commonly used when patients can swallow and do not require injectable administration. Topical products can serve selected localized pain conditions, while regional anesthesia techniques are used for specific surgical procedures and pain management needs. Within the parenteral segment, opioid and non-opioid analgesics can also serve as alternatives in selected clinical situations, depending on pain severity, patient characteristics, and contraindications. However, these options are not interchangeable in every case. Injectable medicines remain important when oral administration is unsuitable or when supervised treatment is required. The extent of substitution depends on clinical guidelines, treatment outcomes, safety considerations, and healthcare professional judgment. Therefore, alternatives can limit demand in certain applications but do not eliminate the need for parenteral analgesics.

Geographical expansion provides moderate growth opportunities for parenteral analgesics manufacturers, particularly in countries where hospital infrastructure, surgical services, and access to injectable medicines continue to develop. Companies can expand through product registrations, distribution agreements, local manufacturing, and partnerships with hospital suppliers. North America and Europe have established healthcare systems and regulatory frameworks, while Asia Pacific offers opportunities linked to expanding healthcare access and pharmaceutical manufacturing capacity. However, market entry requires compliance with country-specific approval procedures, pricing requirements, and distribution rules. Manufacturers must also account for local procurement practices, competition from generic suppliers, and the availability of qualified healthcare professionals. Reliable supply is important because injectable medicines are used in hospitals and emergency care, where interruptions can affect treatment availability. Geographic expansion therefore depends on regulatory readiness, supply chain capacity, local partnerships, and the ability to offer products at prices suitable for healthcare providers.

Analyst Perspective

The parenteral analgesics market is supported by demand for injectable pain medicines in surgical procedures, emergency care, and post-operative recovery. Opioid analgesics hold a leading position due to their use in severe pain management, while non-opioid formulations are gaining demand as part of multimodal pain management. Hospitals remain the primary end users, supported by established clinical infrastructure and supervised medicine administration. Product availability, generic drug competition, regulatory compliance, and the use of injectable analgesics across healthcare facilities will shape market growth.

Drug Class Insights

The opioid analgesics segment dominated the parenteral analgesics industry with a revenue share of 67.0% in 2025, supported by the use of injectable opioids for severe acute pain, post-operative recovery, trauma care, and emergency treatment. Intravenous administration allows healthcare professionals to adjust doses according to patient response and clinical requirements. These medicines are also used when oral administration is unsuitable or controlled pain relief is required. Established clinical use, hospital availability, and the presence of generic manufacturers support demand. In addition, injectable formulations serve patients who require supervised pain management in hospital environments. Hospital procurement practices and the availability of different opioid formulations also support segment demand. However, prescribing controls and the risk of adverse effects require careful monitoring. The continued use of injectable opioids in severe pain management supports their leading position.

The non-opioid analgesics segment is projected to grow at the fastest CAGR of 8.1% during the forecast period, driven by increasing use in multimodal pain management, demand for alternatives to opioids, and wider application in post-operative and acute pain treatment. Hospitals use injectable non-opioid medicines when clinically appropriate to manage pain while limiting opioid exposure. Injectable acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) provide options for selected pain conditions. Their use in surgical recovery and emergency care supports demand across hospital departments. Greater attention to opioid-related adverse effects also supports the use of non-opioid treatment options. Manufacturers can address this demand through generic product development, additional injectable formulations, and reliable supply to hospitals. However, product selection remains dependent on patient characteristics, clinical indications, contraindications, and treatment protocols.

Route of Administration Insights

The intravenous (IV) segment dominated the parenteral analgesics market with a revenue share of 67.0% in 2025, supported by its use in surgical procedures, emergency care, and post-operative pain management. IV administration allows rapid delivery of analgesics into the bloodstream and enables dose adjustment based on patient response. Hospitals use this route when patients cannot take oral medicines or require controlled pain relief. Its use in operating rooms, intensive care units, and emergency departments supports demand. IV formulations also support multimodal pain management through the administration of opioid and non-opioid medicines. Established clinical practices, hospital infrastructure, and the availability of generic injectable products further support segment demand. These factors maintain the role of IV administration in hospital-based pain management.

The subcutaneous (SC) segment is expected to grow at a CAGR of 8.7% during the forecast period, driven by demand for injectable medicines that can be administered into the tissue beneath the skin. This route offers an option when oral administration is unsuitable and intravenous access is not required or readily available. Subcutaneous administration can support pain management in selected palliative care and chronic pain situations, depending on the medicine and clinical protocol. Its use can reduce the need for repeated venous access and support medicine administration outside acute hospital care when appropriate. Product development focused on suitable formulations and dosing options can further support segment growth. However, adoption depends on approved indications, medicine-specific administration requirements, and clinical suitability.

Application Insights

The acute pain segment dominated the parenteral analgesics industry with a revenue share of 76.6% in 2025, supported by demand for pain management during surgery, emergency treatment, trauma care, and post-operative recovery. Injectable analgesics provide an option when patients require rapid pain relief or cannot take oral medicines. Hospitals use opioid and non-opioid formulations according to pain severity, patient condition, and clinical requirements. The need for supervised medicine administration in operating rooms and emergency departments also supports segment demand. Established treatment protocols and the availability of generic injectable products further contribute to product use. In addition, multimodal pain management supports the use of different analgesic classes during recovery. These factors maintain acute pain as a major application of parenteral analgesics across hospital care.

The chronic pain segment is projected to grow at the fastest CAGR of 7.2% during the forecast period, driven by the need for pain management in selected patients with persistent conditions and limited suitability for oral medicines. Injectable analgesics can support treatment when oral administration is difficult or when clinical circumstances require a parenteral route. Demand is also linked to palliative care, specialist pain services, and hospital treatment for patients with complex pain management needs. Subcutaneous administration can provide an option for selected patients when supported by the medicine's approved use and clinical protocol. Greater attention to individualized pain management also supports the use of different treatment options. However, parenteral analgesics are not suitable for all chronic pain conditions, and their use depends on patient assessment, safety considerations, and treatment goals.

End User Insights

The hospitals segment dominated the parenteral analgesics market with a revenue share of 74.3% in 2025, supported by the use of injectable pain medicines in surgical procedures, emergency care, and inpatient treatment. Hospitals manage patients with severe acute pain who require supervised medicine administration and dose adjustment. The availability of operating rooms, recovery units, and intensive care facilities supports the use of intravenous and other injectable analgesics. Hospitals also treat trauma cases and patients who cannot take oral medicines. Access to opioid and non-opioid formulations allows healthcare professionals to select treatments based on clinical requirements. Established procurement systems and demand for reliable medicine supplies further support segment revenue. In addition, hospital-based monitoring helps manage adverse effects associated with injectable analgesics, supporting their use across different departments.

To learn more about this report, Download Free Sample Report

The ambulatory surgical centers segment is projected to grow at the fastest CAGR of 8.0% during the forecast period, driven by the growing use of outpatient procedures and the need for pain control during recovery. These centers require injectable analgesics to manage pain during and after surgery, particularly when patients need supervised treatment before discharge. The use of multimodal analgesia supports the selection of opioid and non-opioid medicines according to procedure type and patient needs. Growth in outpatient surgical services also increases the need for medicines that support pain management within shorter care periods. Reliable access to ready-to-administer formulations can help reduce preparation requirements and support clinical workflows. However, product selection depends on approved indications, patient safety, and facility protocols. These factors support demand for parenteral analgesics in ambulatory surgical care.

Regional Insights

North America dominated the parenteral analgesics market with a revenue share of 41.2% in 2025, supported by established hospital infrastructure, a high volume of surgical procedures, and broad access to injectable medicines. The presence of pharmaceutical manufacturers, including Pfizer Inc., Baxter International Inc., and Mallinckrodt Pharmaceuticals, contributes to product availability across opioid and non-opioid analgesic categories. Demand is supported by the use of injectable pain medicines in emergency care, post-operative recovery, and inpatient treatment. The adoption of multimodal pain management also supports the use of non-opioid injectable formulations. In addition, established pharmaceutical distribution networks and hospital procurement systems support the supply of parenteral analgesics across the region.

To learn more about this report, Download Free Sample Report

U.S. Parenteral Analgesics Market Trends

The United States is a key contributor to the North America parenteral analgesics industry, due to its large hospital network and established surgical care services. Demand is supported by injectable medicines used in emergency departments, operating rooms, and post-operative recovery units. The presence of pharmaceutical companies and generic injectable drug manufacturers supports product supply across different analgesic classes. Hospitals use intravenous acetaminophen, injectable NSAIDs, and opioid analgesics according to clinical requirements. The use of multimodal pain management also supports demand for non-opioid injectable options. However, opioid safety requirements and competition among generic suppliers influence prescribing and procurement decisions.

Europe Parenteral Analgesics Market Trends

Europe represents an important regional market due to its established healthcare systems, hospital services, and access to prescription injectable medicines. Surgical procedures, emergency treatment, and inpatient care support the use of parenteral analgesics across the region. Demand includes opioid medicines for severe pain and non-opioid formulations for selected acute pain conditions. Pharmaceutical manufacturers and generic drug suppliers contribute to product availability across national markets. Hospital procurement systems and medicine pricing policies influence supplier selection and product purchasing. Differences in national approval procedures, reimbursement practices, and prescribing requirements affect the availability and use of injectable analgesics across European countries.

The United Kingdom parenteral analgesics market is supported by hospital-based surgical care, emergency treatment, and the use of injectable medicines for post-operative pain. Intravenous analgesics are used when patients require supervised pain relief or cannot take oral medicines. Demand includes opioid products for severe pain and non-opioid medicines used in multimodal pain management. Established hospital procurement processes influence product selection and supplier relationships. The use of generic injectable medicines supports purchasing across healthcare facilities. Controlled drug requirements, clinical prescribing guidance, and medicine availability influence the use of parenteral analgesics in the country.

The parenteral analgesics market in Germany benefits from established hospital infrastructure, surgical services, and pharmaceutical manufacturing capabilities. Injectable analgesics are used in operating rooms, emergency departments, and inpatient wards to manage pain associated with surgery, trauma, and other acute conditions. Demand spans opioid and non-opioid formulations selected according to patient needs and treatment protocols. The presence of pharmaceutical manufacturers and generic medicine suppliers supports competition in hospital drug procurement. Sterile manufacturing standards and product quality requirements influence supplier selection. Healthcare purchasing practices, medicine prices, and the availability of approved injectable formulations affect demand across German hospitals.

France's parenteral analgesics market is supported by hospital care, surgical procedures, and the clinical use of injectable medicines for acute pain management. Parenteral analgesics are used during post-operative recovery and emergency treatment when oral administration is unsuitable or insufficient. Opioid formulations serve selected severe pain conditions, while non-opioid medicines provide additional options for multimodal analgesia. Hospital pharmacies play an important role in procurement and product distribution within healthcare facilities. The presence of generic injectable products supports competition among suppliers. Prescribing requirements, medicine safety monitoring, and the availability of approved formulations influence product selection across French healthcare facilities.

Asia Pacific Parenteral Analgesics Market Trends

The Asia Pacific parenteral analgesics industry is projected to grow at the fastest CAGR of 8.9% during the forecast period, supported by expanding hospital capacity and increasing access to surgical services. Growth in emergency care and inpatient treatment supports demand for injectable analgesics across the region. Rising access to pharmaceutical products and local manufacturing capabilities also contribute to product availability. The use of generic injectable medicines provides hospitals with options across different price levels. Demand varies across countries according to healthcare infrastructure, clinical practices, and access to pain management services. Regulatory requirements, sterile manufacturing capacity, and distribution networks remain important factors affecting regional market development.

Japan's parenteral analgesics market is supported by established hospital services, surgical care, and the use of injectable medicines for supervised pain management. Injectable analgesics are used in post-operative recovery and acute care when rapid or controlled pain relief is required. Demand includes non-opioid medicines and opioid formulations selected according to clinical needs. An established pharmaceutical industry supports the supply of approved injectable products. Hospital purchasing practices and product quality requirements influence competition among manufacturers. Prescribing controls, patient safety considerations, and the availability of alternative pain management treatments affect the use of parenteral analgesics.

The parenteral analgesics market in Chinais supported by hospital capacity, surgical treatment, emergency care, and domestic pharmaceutical manufacturing. Injectable medicines are used to manage post-operative pain, trauma-related pain, and other acute conditions requiring supervised treatment. Local manufacturers and generic drug suppliers contribute to the availability of opioid and non-opioid formulations. The development of domestic sterile manufacturing capabilities also supports product supply to healthcare facilities. Demand differs across urban and rural areas due to variations in hospital resources and access to treatment. Product approvals, controlled substance requirements, and hospital procurement practices influence competition and the availability of injectable analgesics.

Latin America Parenteral Analgesics Market Trends

Latin America's parenteral analgesics industry is supported by hospital admissions, surgical procedures, emergency care, and demand for injectable pain management. Public and private healthcare facilities use parenteral medicines for post-operative recovery and acute pain treatment. Generic injectable analgesics offer hospitals options for managing medicine procurement costs. Regional pharmaceutical manufacturers and international suppliers contribute to product availability. Differences in healthcare infrastructure and access to specialized services affect demand across countries. Import dependence, product registration requirements, distribution costs, and supply continuity influence the availability of injectable analgesics throughout the region.

Brazil's parenteral analgesics market is supported by its large healthcare system, surgical services, emergency departments, and hospital-based pain management. Injectable analgesics are used for post-operative recovery, trauma care, and acute pain conditions requiring supervised administration. Opioid and non-opioid medicines serve different treatment needs based on clinical assessment. Domestic pharmaceutical manufacturers and generic drug suppliers contribute to the supply of injectable formulations. Hospital procurement practices and medicine pricing influence product selection. Regulatory requirements, distribution coverage, and differences in healthcare access across regions affect the availability and use of parenteral analgesics.

Middle East & Africa Parenteral Analgesics Market Trends

The MEA parenteral analgesics industry is supported by hospital treatment, surgical procedures, emergency care, and demand for injectable medicines in acute pain management. Healthcare facilities use parenteral analgesics when patients require supervised administration or cannot take oral medicines. Demand varies across countries according to hospital capacity, healthcare access, and the availability of trained clinical staff. International pharmaceutical suppliers and regional distributors play an important role in product availability. Some markets rely on imported injectable medicines, making distribution and supply continuity relevant factors. Regulatory requirements, procurement budgets, and differences in healthcare infrastructure influence the use of parenteral analgesics across the region.

Saudi Arabia's parenteral analgesics market is supported by hospital infrastructure, surgical treatment, emergency services, and demand for pain management during inpatient care. Injectable analgesics are used in operating rooms, recovery units, and emergency departments for selected acute pain conditions. Both opioid and non-opioid medicines contribute to hospital treatment, depending on pain severity and patient needs. Hospital pharmacies and pharmaceutical distributors support product procurement and availability. Demand is also linked to access to specialized medical services and adherence the established clinical protocols. Controlled medicine requirements, product registration, and supply chain reliability influence the availability of injectable analgesics in the country.

Key Parenteral Analgesics Company Insights

The parenteral analgesics market has a competitive structure, with several pharmaceutical companies supplying injectable opioid and non-opioid medicines. Pfizer Inc.; Fresenius Kabi AG; Mallinckrodt Pharmaceuticals; Hikma Pharmaceuticals PLC; Baxter International Inc.; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Cipla Limited; and Dr. Reddy's Laboratories Ltd. compete through their relevant injectable product portfolios. Competition varies across drug classes, routes of administration, product availability, manufacturing capabilities, regulatory requirements, and geographic presence. Opioid analgesics serve patients requiring treatment for severe pain, while non-opioid formulations support acute pain management and multimodal treatment. Companies with established injectable products, sterile manufacturing capabilities, and hospital supply networks participate in this market.

Key Parenteral Analgesics Companies

The following key companies have been profiled for this study of the parenteral analgesics market.

• Pfizer Inc.

• Fresenius Kabi AG

• Mallinckrodt Pharmaceuticals

• Hikma Pharmaceuticals PLC

• Baxter International Inc.

• Viatris Inc.

• Teva Pharmaceutical Industries Ltd.

• Sun Pharmaceutical Industries Ltd.

• Cipla Limited

• Dr. Reddy's Laboratories Ltd.

Recent Developments

• In July 2025, Hikma Pharmaceuticals PLC launched morphine sulfate injection in prefilled syringes in the U.S. in 2 mg/mL and 4 mg/mL strengths for the management of severe pain requiring opioid analgesic treatment.

• In February 2024, Hikma Pharmaceuticals PLC launched an intravenous combination of acetaminophen and ibuprofen in the U.S. for the relief of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics in adults.

• In February 2024, Hikma Pharmaceuticals PLC launched fentanyl citrate injection in prefilled syringes in the U.S. in 25 mcg/0.5 mL and 50 mcg/mL presentations for short-duration analgesia during anesthesia and the immediate post-operative period, among other approved uses.

Global Parenteral Analgesics Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global parenteral analgesics market report based on drug class, route of administration, application, end user, and region:

• Drug Class Outlook (Revenue, USD Million/Billion, 2021 – 2033)

  • Opioid Analgesics

  • Non-Opioid Analgesics

  • Others

• Route of Administration Outlook (Revenue, USD Million/Billion, 2021 – 2033)

  • Intravenous (IV)

  • Intramuscular (IM)

  • Subcutaneous (SC)

  • Others

• Application Outlook (Revenue, USD Million/Billion, 2021 – 2033)

  • Acute Pain

  • Chronic Pain

• End User Outlook (Revenue, USD Million/Billion, 2021 – 2033)

  • Hospitals

  • Ambulatory Surgical Centers

  • Specialty Clinics

  • Others

• Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The parenteral analgesics market size is estimated using the commodity flow approach, supported by product-level revenue analysis. The study begins by identifying key manufacturers and their injectable analgesic products across opioid analgesics, non-opioid analgesics, and other drug classes. Product volumes and prices are assessed across intravenous, intramuscular, and subcutaneous formulations to estimate the value of products supplied to each country. The analysis considers imports, exports, domestic production, and product availability to assess the flow of injectable analgesics into healthcare markets. Product-level information is collected from company annual reports, regulatory databases, product disclosures, and other verified sources. The estimated value is further assessed by application, including acute and chronic pain, as well as by end users such as hospitals, ambulatory surgical centers, and specialty clinics. Country-level estimates are aggregated to calculate regional and global market size. The results are cross-checked against manufacturer revenues, generic competition, and hospital demand to maintain consistency.

Estimation Model

To learn more about this report, Download Free Sample Report

Delivered Customizations

This report has been delivered with the following In-depth customizations